LSTA

#4529
Lisata Therapeutics, Inc. - Common Stock
3.2 9 USD
-0.60%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
3.17
3.29
Year Range
1.81
5.06
Daily Change
-0.60%
Monthly Change
+2.49%
6 month change
+60.49%
Year Change
+17.92%
Previous Close
3.3 1
Open
3.2 5
Low
3.1 7
High
3.2 9
Volume
10
Open full chart Full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 29.96 M
  • Employee 21
  • Founded 1980
  • CEO N/A
  • Website www.lisata.com
  • Headquarter Delaware, United States
  • FIGI BBG000BNVDR4
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-0.97
Price to sales ratio
95.05

Lisata Therapeutics, Inc. - Common Stock

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

News